UK Markets close in 8 hrs 28 mins
  • FTSE 100

    6,715.42
    0.00 (0.00%)
     
  • FTSE 250

    20,793.72
    0.00 (0.00%)
     
  • AIM

    1,198.09
    +10.59 (+0.89%)
     
  • GBP/EUR

    1.1241
    -0.0040 (-0.35%)
     
  • GBP/USD

    1.3670
    -0.0060 (-0.4402%)
     
  • BTC-GBP

    22,476.95
    +211.24 (+0.95%)
     
  • CMC Crypto 200

    605.79
    -4.20 (-0.69%)
     
  • S&P 500

    3,853.07
    +1.22 (+0.03%)
     
  • DOW

    31,176.01
    -12.37 (-0.04%)
     
  • CRUDE OIL

    52.43
    -0.70 (-1.32%)
     
  • GOLD FUTURES

    1,860.00
    -5.90 (-0.32%)
     
  • NIKKEI 225

    28,631.45
    -125.41 (-0.44%)
     
  • HANG SENG

    29,426.05
    -501.71 (-1.68%)
     
  • DAX

    13,906.67
    -14.70 (-0.11%)
     
  • CAC 40

    5,590.79
    -37.65 (-0.67%)
     

Saniona’s Ownership Stake in Scandion Oncology Reduced Below 5% Following Scandion’s Successful Rights Issue

Saniona AB
·1-min read

PRESS RELEASE

December 16, 2020

Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced the reduction of its ownership stake in Scandion Oncology A/S (Spotlight Stock Market: SCOL) below 5%. This reduction is a result of a rights issue completed by Scandion Oncology on December 15, 2020.

Scandion Oncology was formed in 2017 through a spin-out of assets from Saniona. These assets included SCO-101, a first-in-class molecule targeting chemotherapy resistance, as well as related analogues and technical expertise.

For more information, please contact

Trista Morrison, Chief Communications Officer, Saniona. Office: + 1 (781) 810-9227. Email: trista.morrison@saniona.com

The information was submitted for publication, through the agency of the contact person set out above, at 8:00 CET on December 16, 2020.

About Saniona
Saniona is a biopharmaceutical company focused on discovering, developing, and delivering innovative treatments for rare disease patients around the world. The company’s lead product candidate, Tesomet, is in mid-stage clinical trials for the rare diseases Prader-Willi syndrome and hypothalamic obesity. Saniona also has a broad pipeline derived from its proprietary ion channel discovery platform, with lead candidate SAN711 entering Phase 1 studies for rare neuropathic disorders. Saniona intends to develop and commercialize its rare disease products internally. The company has out-licensed other programs, which may provide future supplemental revenue. Saniona is based in Copenhagen, Denmark and Boston, Mass., U.S. The company’s shares are listed on Nasdaq Stockholm Small Cap (OMX: SANION). Read more at www.saniona.com.

Attachment